Literature DB >> 16146725

Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?

Tariq I Mughal1, John M Goldman.   

Abstract

Clinically chronic myeloid leukemia is a biphasic or triphasic disease that is usually diagnosed in the initial 'chronic', 'indolent' or 'stable' phase and then spontaneously evolves after some years into an advanced phase. This advanced phase can sometimes be subdivided into an earlier accelerated phase and a later blast phase or blast transformation--in about one-half of patients the chronic phase transforms unpredictably and abruptly to a blast phase, while in the other half of patients, the disease evolves somewhat more gradually, through an accelerated phase, which may last for months or years, before a blast phase ensues; this may have myeloblastic or lymphoblastic features. Although much is now known about the molecular biology of the disease, the molecular basis of disease progression is still obscure. The popular thinking has been that one or more probably a sequence of additional genetic events occurs in the BCR-ABL positive clone. When the critical combination of additional events is achieved, clinically definable transformation occurs. Here we review what is known of the mechanisms underlying the evolution of chronic myeloid leukemia from a chronic phase to a blast transformation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16146725     DOI: 10.2741/1791

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  4 in total

1.  A case report of a 33-year chronic phase survivor of chronic myeloid leukemia.

Authors:  Ou Ji; Qun Shen; Ya-Cheng Zhang; Jian-Min Ji; Guang-Rong Zhu; Lin Lin; Xiang-Tu Kong; Wen Xia; Peng-Jun Jiang
Journal:  Med Oncol       Date:  2011-02-27       Impact factor: 3.064

Review 2.  Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Tiziano Barbui; Omar Abdel-Wahab; Robert Kralovics; Catriona Jamieson; Hans-Michael Kvasnicka; Ann Mullaly; Raajit Rampal; Ruben Mesa; Jean-Jacques Kiladjian; Michael Deininger; Josef Prchal; Rüdiger Hehlmann; Giuseppe Saglio; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-11-19

3.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.

Authors:  Hagop Kantarjian; Jorge Cortes; Dong-Wook Kim; Pedro Dorlhiac-Llacer; Ricardo Pasquini; John DiPersio; Martin C Müller; Jerald P Radich; H Jean Khoury; Nina Khoroshko; M Brigid Bradley-Garelik; Chao Zhu; Martin S Tallman
Journal:  Blood       Date:  2009-04-15       Impact factor: 22.113

4.  Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease.

Authors:  Melissa Kristine Middleton; Alicia Marie Zukas; Tanya Rubinstein; Michele Jacob; Peijuan Zhu; Liang Zhao; Ian Blair; Ellen Puré
Journal:  J Exp Med       Date:  2006-10-16       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.